UNSPSC 51172485: Agalsidase alfa

Agalsidase alfa is a recombinant human ?-galactosidase indicated in the treatment of Fabry disease.

UNSPSC 51172485 Agalsidase alfa, a Commodity code, identifies a single pharmaceutical product that state and local governments procure primarily through health departments, county health facilities, and public health agencies serving patient populations with rare genetic disorders. The code shows minimal recent activity in the state and local procurement record; the opportunities posted under this code are largely unrelated to agalsidase alfa itself and include a county purchasing office relocation notice, a county health department's procurement of naloxone and drug deactivation systems, a fire department's request for BLS/ALS pharmaceuticals and vending services, and a forensic laboratory's procurement of drug reference standards. None of these solicitations specifically target agalsidase alfa, a recombinant enzyme replacement therapy used to treat Fabry disease. The mismatch between the code's nominal scope and the actual procurement opportunities posted under it suggests that either the code has been misapplied to these records or that state and local agencies rarely use this specific commodity code when buying agalsidase alfa or other specialty pharmaceuticals.

Because the source contains no recent opportunities directly soliciting agalsidase alfa, no geographic concentration, issuing-body pattern, or representative solicitation details are available to characterize active procurement under this code. Vendors evaluating this code should treat the current posting activity as a signal that state and local health procurement under UNSPSC 51172485 is not seeing active solicitation traffic at present.